Faldaprevir (sodium)

Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection[1][2].

Product Specifications

CAS Number

[1215856-44-2]

Product Name Alternative

BI 201335 (sodium)

UNSPSC

12352005

Target

HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/faldaprevir-sodium.html

Smiles

O=C([C@H]1N(C[C@@H](C1)OC2=CC(C3=CSC(NC(C(C)C)=O)=N3)=NC4=C2C=CC(OC)=C4Br)C([C@H](C(C)(C)C)NC(OC5CCCC5)=O)=O)N[C@]6([C@@H](C6)C=C)C(O[Na])=O

Molecular Formula

C40H48BrN6NaO9S

Molecular Weight

891.80

References & Citations

[1]Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335) . J Med Chem. 2010 Sep 9;53 (17) :6466-76.|[2]Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18 (8) :1015-9.